Table 4.
Substance use disorder groups with comorbid severe mental illness | Major depressive disorder (n = 36) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Schizophrenia (n = 37) | Bipolar disorder (n = 34) | ||||||||
SF-36 Dimension |
Adjusted R2 | IV | ß standardized | Adjusted R2 | IV | ß standardized | Adjusted R2 | IV | ß standardized |
Physical Functioning | 0.326 | Medical disease comorbidity | −0.588*** | ||||||
Social Functioning | 0.408 | Positive symptoms (PANSS) | −0.650** | ||||||
Medical disease comorbidity | −0.432* | ||||||||
Role-Physical | 0.140 | Suicide attempts | −0.407* | 0.193 | Suicide attempts | −0.467** | 0.209 | Medical disease comorbidity | −0.482** |
Role-Emotional | 0.476 | Medical disease comorbidity | −0.718** | ||||||
Mental Health | 0.347 | Medical disease comorbidity | −0.638* | 0.427 | Severity of substance use disorder (DAST-20) | −0.689** | 0.482 | Depressive symptoms (HDRS) | −0.719** |
Vitality | 0.448 | Drug relapses | −0.669* | ||||||
Bodily Pain | 0.247 | PANSS composite score | −0.532* | 0.177 | Depressive symptoms (HDRS) | −0.469* | |||
General Health | 0.222 | Medical disease comorbidity | −0.494** |
SF-36: Short Form Health Survey
In all cases Tolerance values were higher than 0.954 and Variance Inflation Factor were higher than 1
*p < 0.05, **p < 0.01; ***p < 0.001